RSS Feeds
Review of Comparative Effectiveness of Treatments to Prevent Fractures
- John L. Stock, MD;
- John L. Mershon, MD; and
- Michael Jay Schoenfeld, MA
- From Eli Lilly and Company, Indianapolis, IN 46285.
TO THE EDITOR:
We read with interest the recent comprehensive systematic review on osteoporosis therapies by MacLean and colleagues (1), and we would like to bring 3 issues to your attention.
The article describes an increased risk for “mild cardiac events” with raloxifene, based on a combination of 4 events (tachycardia, chest pain, palpitations, and vasodilatation) across 6 studies (n = 2686). Criteria for selecting these particular events and trials are not given. The trials selected do not include pivotal randomized, placebo-controlled trials, such as the MORE (Multiple Outcomes …
